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A Comparison of Adaptive Designs in Clinical Trials:
when Multiple Treatments are tested in Multiple Stages
Sukyung Park, M.S.Stat
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Supervisor: Peter Mu¨ller
In recent times, there has been an increasing interest in adaptive de-
signs for clinical trials. As opposed to conventional designs, adaptive designs
allow flexible design adaptation in the middle of a trial based on accumulated
data. Although various models have been developed using both frequentist
and Bayesian perspectives, relative statistical performances of adaptive de-
signs are somewhat controversial and little is known about those of Bayesian
adaptive designs. Most comparison studies also focused on single experimental
treatment rather than multiple experimental treatments. In this report, both
frequentist and Baysian adaptive designs were compared in terms of statistical
power by a simulation study, assuming the situation when multiple experi-
mental treatments are tested in multiple stages. The designs included in the
current study are group sequential design (frequentist), adaptive design based
on combination tests (frequentist), and Bayesian adaptive design (Bayesian).
Based upon the results under multiple scenarios, the Bayesian adaptive design
vi
showed the highest power, and the design based on combination tests per-
formed better than group sequential designs when proper interim adaptation
could be conducted to increase power.
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Chapter 1
Introduction
Adaptive designs are statistical methodologies for clinical trials, in-
creasingly recognized as useful tools for investigating experimental drugs, pro-
cedures, and medical devices. They allow that accumulated data can be ana-
lyzed in the middle of a trial so that appropriate interim adaptation is made
during its course. Interim analyses are often recommended in clinical trials be-
cause the total process of trials can be adjusted to improve the probability of
successful completion. This provides ethical and economical benefits [1]. For
example, it would be desirable to move the process rapidly if an experimental
drug shows overwhelming efficacy in the middle of a trial. With adaptive de-
signs, trials can be stopped early for superiority, a treatment can be dropped
for inferiority, and a samples size can be modified to increase statistical power.
Conventional designs such as fixed-sample designs usually perform one final
analysis without interim analyses or adaptation. Since they strictly conduct
a trial only as planned, designs cannot be modified to improve efficiency or
response to unexpected situations [2].
Adaptive designs incorporate multiple testing to allow interim analyses.
This often results in a significant inflation of the overall type I error rate, which
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can be a serious problem with respect to statistical validity. Thus, adaptive
designs have been developed to provide more flexibility without compromising
the overall type I error rate. One approach in adaptive designs is a group
sequential design which stops a treatment at any interim analysis for either
futility or superiority [3, 4, 5, 6]. Group sequential models were initially de-
signed to allow early stopping for treatment superiority, but can be extended
to incorporate treatment selection in more general settings. Another popular
class of methods are adaptive designs based on combination tests, which were
developed to provide additional flexibility compared to the group sequential
designs [7, 8, 9, 10]. Such designs usually combine evidence from stage-wise
data using a specific combination function of p-values. By introducing p-values
as test statistics, a wide range of design adaptation is possible at interim anal-
yses. A Bayesian adaptive approach also can be considered as an alternative to
these designs [11, 12]. The Bayesian approach to inference is directly based on
the data without concerns about type I error rate. Most design restrictions in
frequentist designs, such as group sequential and combination test approaches,
are related to the issue of controlling type I error rate. Therefore, more flexible
designs can be constructed using Bayesian adaptive models to address various
aspects of interim adaptation.
Although extensive research has been carried out on adaptive designs,
debate continues about statistical performance of adaptive designs. Tsiatis and
Mehta (2003) [13] first discussed systematically how group sequential designs
can outperform adaptive designs based on insufficient statistics, i.e., p-values,
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if more interim analyses are allowed for group sequential designs. Jennison
and Turnbull (2003, 2006)[14, 15] showed by simulation that standard group
sequential approaches can be more efficient than adaptive test based on com-
bination test approaches. Kelly et al. (2005) [16] compared both designs in
practical settings, indicating that the difference in power is not identified as
long as asymptotic assumptions for test statistics are satisfied. For trials with
multiple treatments, however, Friede and Stallard (2008) [35] reported that
adaptive designs using combination tests can be better than group sequential
designs in spite of the use of insufficient statistics, when it is believed a priori
that all treatments are effective. Most comparisons were based on frequentist
adaptive designs, and little is known about relative performances of Bayesian
adaptive models in terms of statistical power.
The purpose of this report is to compare adaptive designs by simulation
including both frequentist and Bayesian methods. The specific methods con-
sidered in this study are as follows: Pocock’s [3] and O’Brien and Fleming’s
[4] for the group sequential design, Bretz et al. (2009) [1] model for the combi-
nation test approach, and a hierarchical Bayesian model based on Thall et al.
(2003) [12] for the Bayesian adaptive design. The report is also aimed to inves-
tigate statistical performances of adaptive designs when multiple treatments
are tested in multiple stages. Clinical trials become more complex than before
and often involve two or more experimental treatments. However, there have
been only a few discussions about testing multiple treatments using adaptive
designs. The present report has been organized in the following way. The
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chapter two first gives a brief description of frequentist adaptive methods in
clinical trials, and the chapter three introduces a model for the Bayesian adap-
tive design. Both chapter two and three also include implementations when
multiple treatments are tested in multiple stages. The chapter four summa-
rizes scenarios of the comparison study and reports major findings. The last
section concludes by discussing limitation and extensions.
4
Chapter 2
Frequentist Adaptive Designs
This chapter introduces two frequentist adaptive designs in clinical tri-
als, which are used for the comparison study in this report. The first sec-
tion illustrates a group sequential design, and the second section describes an
adaptive design based on combination tests. For multiplicity issue of multiple
hypotheses, the last section discusses the closure principle and its applications.
2.1 Group Sequential Design
Classical group sequential designs monitor superiority of an experimen-
tal treatment at each interim analysis. In a clinical trial, inferences are often
made by statistical hypothesis tests, and group sequential designs examine
whether or not there is evidence against a null hypothesis in accumulating
data [3, 4]. In contrast to the fixed-sample designs allowing one final analy-
sis from fully pre-planned process, group sequential designs can be considered
more flexible in that a trial can be stopped at any interim analysis in response
to what interim data demonstrate. However, repeating hypothesis test can
increase the probability of falsely rejecting the true null hypothesis, which is
also known as the type I error rate. Group sequential designs usually use
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different critical regions to control overall type I error rate associated with
multiple interim analyses. This section briefly describes two classical group
sequential designs: Pocock’s design [3] and O’Brien and Fleming’s design [4].
More details about group sequential designs can be found in Yin (2012)[2] and
Jennison and Turnbull (2000)[18].
2.1.1 Pocock’s Design
The Pocock’s Design(1977)[3] is a group sequential design which as-
sumes equal stopping boundaries across all stages. Although the design was
proposed originally for a two-sided test, it can be easily extended to a one-sided
test. Suppose that we are interested in testing superiority between two treat-
ments when a trial is scheduled up to K stages in advance. We assume that
treatment 1 is the experimental treatment, while treatment 0 is the standard
treatment. At each stage, outcomes are independent normal random variables
such that:
Y1ij ∼ N(µ1, σ2), Y0ij ∼ N(µ0, σ2), i = 1, 2, .., n, j = 1, 2, .., K (2.1)
where Y1ij and Y0ij denote i-th observation of treatment 1 and 0 at stage j,
respectively. Treatment 1 and 0 have the true mean µ1 and µ0. For simplicity,
we assume that the variance σ2 and the sample size n are known and equivalent
across all treatments at all stages. The only unknown quantities are the true
treatment means, while others should be determined in advance before starting
a trial.
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According to the notation defined above, the one-sided test for the
treatment difference refers to testing the hypotheses
H0 : µ1 − µ0 ≤ 0, H1 : µ1 − µ0 > 0 (2.2)
Now let Nk = nk denote the cumulative sample size up to stage k
for each treatment. Conditioned on the null hypothesis, the standardized test
statistic Zk for the k-th interim analysis based on the all previous observations
is given by:
Zk =
1√
2Nkσ2
k∑
j=1
n∑
i=1
(Y1ij − Y0ij) = Y¯1 − Y¯0√
2σ2/Nk
(2.3)
where Zk is tested at each stage against some critical value ck. In the case
of rejecting the null hypothesis at interim stages (Zk ≥ ck), the trial is early
stopped for superiority. Otherwise (Zk < ck), the trial proceeds to stage k+1
until the stage reaches the maximum number of stages, K.
ck is assumed to be constant across all stages as Pocock(1977)[3] pro-
posed, but should be larger than the single stage significant level α due to
the possible inflation of the overall type I error rate. For one-sided testing,
Pocock’s constant ck = cpo, k = 1, 2, .., K can be computed numerically ac-
cording to the following definition:
α = P (Zk ≥ cpo at any k in a sequential order |H0) (2.4)
This can be also obtained by solving K equations with respect to the stage
wise α level, αk [2]. For example, when maximum two stages are scheduled,
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cpo can be computed numerically by considering the following two equations.
α1 = P (Z1 ≥ cpo|H0), (2.5)
α2 = α = P (Z1 < cpo, Z2 ≥ cpo|H0) + α1 (2.6)
2.1.2 O’Brien and Fleming’s Design
O’Brien and Fleming’s Design has the exactly same procedure with
Pocock’s, except the critical values are not constant across K stages [4]. They
proposed the critical value at stage k, ck, such that
ck = cof
√
K/k (2.7)
where cof is a constant and K is the maximum number of stages. This specifi-
cation is based on the idea that the rejection criterion should be more stringent
at the earlier interim analyses due to the limited number of observations. As
the trial proceeds, this criterion is relaxed by increasing
√
K/k so that the
null hypothesis is more likely rejected than earlier testing stages. For one-sided
testing, O’Brien and Fleming’s constant cof can be computed numerically ac-
cording to the following definition.
α = P (Zk ≥ cof
√
K/k at any k in a sequential order |H0) (2.8)
Note that this can be also obtained by solving K equations iteratively with
respect to the individual significance level of each stage k.
In general, it is expected that O’Brien and Fleming’s design has more
statistical power than Pocock’s design because critical values decrease as trial
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proceeds. In most cases, the values at the final stage in O’Brien and Fleming’s
are smaller than those in Pocock’s, whereas they are greater than those in
Pocock’s at earlier stages. As such, it is more likely for the null hypothesis
to be rejected in O’Brien and Fleming’s design, indicating that the overall
statistical power of O’Brien and Fleming’s is higher than the overall statistical
power of Pocock’s.
2.2 Adaptive Design based on Combination Tests
Although group sequential designs are more flexible than fixed-sample
designs, there are still some aspects required to specify in advance, e.g., sample
sizes at each stage. The adaptive designs based on combination tests have been
developed to overcome this limitation and provide more flexibility at interim
stages [7, 8, 9, 10]. The key idea of the combination tests is combining stage-
wise p-values according to the conditional invariance principle [19, 10, 20]. By
introducing p-values as test statistics, many design features such as sample
sizes can be modified at interim stages without inflation of the overall type I
error rate [22]. Thus, although p-values are not sufficient statistics, adaptive
designs can increase statistical power at interim stages if appropriate design
modifications are applied. This section describes the conditional invariance
principle and the adaptive design of Bretz et al. (2009) [1] based on the
combination test approach. More detailed information can be found in Bretz
et al. (2009) and the references therein.
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2.2.1 Conditional Invariance Principle
The conditional invariance principle controls the type I error rate when
interim results or modifications are unknown in advance. According to the
conditional invariance principle, an α level test can be constructed without
knowing adaptation rules, if distributions of test statistics are known and con-
ditionally invariant with respect to the interim adaptation [20]. For example,
combination test approaches usually exploit stage-wise p-values, which are al-
ways uniformly distributed under the pre-specified null hypothesis. Since this
distributional aspect does not change after interim adaptation, it can be said
that distributions of p-values are conditionally invariant with respect to the
interim data and the mid-term design adaptation. Knowing that distributions
of test statistics are (conditionally) independent of interim analyses, we can
now construct an α level test in terms of p-values. The more detailed example
will be following, but we also refer to Liu et al. (2002) [21] for more rigorous
discussion about the conditional invariance principle.
2.2.2 Combination Test Approach
A combination test approach is a statistical method which combines
stage-wise p-values through a pre-specified combination function. It allows
early stopping for futility or superiority at interim stages. For simplicity, here
we illustrate an adaptive design for a single null hypothesis, which is tested in
two stages [1].
Suppose that there are two treatments, where one is experimental and
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the other is standard. Similar to group sequential designs, we are interested
in testing one-side null hypothesis H0 for the treatment difference. Let p1 and
p2 be the p-values from stage 1 and 2 data, respectively. At the interim stage,
a combination test approach examines whether a trial can be early stopped or
proceed to the second stage by comparing p-values to α0 and α1. α0 and α1 are
early stopping boundaries such that 0 < α1 ≤ α0 ≤ 1. If p1 > α0, then H0 is
early accepted and the trial stops for futility of the experimental treatment. If
p1 ≤ α1, then H0 is early rejected and the trial stops for superiority. Otherwise,
α1 < p1 ≤ α0 and the trial continues to the second stage to combine stage-
wise p-values through the pre-specified combination function C(p1, p2). This
combination function defines the critical region as C(p1, p2) ≤ c, where the
corresponding critical value c is determined by solving the following equation:
α1 +
∫ α0
α1
∫ 1
0
1[C(x,y)≤c]dydx = α (2.9)
which maintains the overall type I error rate at α regardless of the design
adaptation after interim analyses.
Although p-values can be combined in many different ways, there are
two prominent examples of combination functions in general. One is Fisher’s
product criterion C(p1, p2) = p1p2 [10], and the other is the weighted inverse
normal combination function [9]. The weighted inverse normal combination
function has the following form:
C(p1, p2) = 1− Φ[w1Φ−1(1− p1) + w2Φ−1(1− p2)], (2.10)
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where w1 and w2 denote pre-specified weights such that w
2
1 + w
2
2 = 1, and Φ
denotes the cumulative distribution function of the standard normal distribu-
tion. The weights of this function are often defined as w21 = n1/(n1 +n2), w
2
2 =
n2/(n1 + n2), where n1 and n2 indicate the pre-planned sample size for the
stage1 and 2, respectively. The weighted inverse normal combination function
with this weight definition is equivalent to a classical group sequential when a
single null hypothesis is considered without any interim adaptation [24].
The choice of α0 for the futility stopping is sometimes important and
there can be two different stopping rules for futility: Binding versus non-
binding rules. Binding futility rules choose α0 < 1, allowing a futility stop at
the interim analysis whenever p1 > α0. Alternatively by fixing α0 = 1, non-
binding rules provide more flexibility in interim stopping criteria, but they
often result in less statistical power than binding rules.
2.3 Multiplicity and the Closure Principle
Clinical designs in practice involve the test of multiple hypotheses.
When several experimental treatments need to be compared to one single
standard treatment, multiple null hypotheses are constructed and tested si-
multaneously. Multiplicity, also known as the multiple testing problem, occurs
in this situation because simply performing an α-level test for each hypothesis
leads to inflation of the probability of rejecting at least one true null hypoth-
esis, i.e., the family-wise error rate. For instance, suppose that we test two
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hypotheses simultaneously with α = 0.05. Then the probability of at least
one null hypothesis being rejected is 1− (0.95× 0.95) = 0.0975, a much larger
value than that of one single null hypothesis. However, we want this rate to
be within α when multiple treatments are tested in multiple stages.
The closure principle is a general methodology to handle this issue,
which strongly controls the family-wise error rate at a pre-specified α level
[25]. It considers all possible intersection hypotheses and reject an elementary
(original) hypothesis only when all relevant intersections are rejected at α level.
More precisely, the test procedure is conducted as follows:
1. Let K be the number of hypotheses, and Hk denotes the kth hypothesis
for every k = 1, . . . , K.
2. Construct all intersection hypotheses. That is, define HI = ∩k∈IHk for
every subset I ⊂ {1, 2, . . . , K}.
3. Perform an α-test for each intersection hypothesis.
4. Reject Hk if all the intersection hypotheses HI where k ∈ I are rejected.
2.3.1 An Example for Group Sequential Design
Group sequential designs can be extended to incorporate multiple treat-
ments in many ways (e.g., [26, 27]), and here is one example suggested for the
closure principle. Note that the following design is summarized as a step-by-
step algorithm in the section 4.1.2. Suppose we compare two experimental
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treatments to one single standard in stage K using Pocock’s group sequential
design. The experimental treatments are named treatment 1 and 2, while the
standard is treatment 0. Based on the case of the previous section, there are
two elementary null hypotheses, H0j = µj − µ0, j = 1, 2 and three intersec-
tion hypotheses, {H01, H02, H01
⋂
H02}. At each interim stage, all intersection
hypotheses are individually tested based on the Pocock’s critical value. Note
that any proper multiplicity adjustment such as Bonferroni correction [28] can
be applied for intersection hypotheses involving more than one elementary hy-
pothesis. When all intersection hypotheses that includes H0j are rejected at
this interim analysis, we reject the elementary null hypothesis H0j and stop
the trial early for the superiority of the treatment j. Otherwise, the trial con-
tinues to the next stage unless it reaches the maximum number of stage K.
The multiple treatment case for O’Brien and Fleming’s design follows exactly
the same procedure except using different critical values.
2.3.2 An Example for Combination Test Approach
The closure principle also provides an α level test for adaptive designs
for combination tests with multiple null hypotheses [1, 23]. The following
procedure also can be found as a step-by-step algorithm in the section 4.1.3.
Suppose two experimental treatments are compared to one single standard in
two stages. There are two elementary null hypotheses, H0j = µj−µ0, j = 1, 2
and three intersection hypotheses, {H01, H02, H01
⋂
H02}. At the interim stage,
all intersection hypotheses are tested individually using p-values based on the
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data from the first stage. That is, all intersection hypothesis are examined
whether their p-values are greater than stopping boundary for futility α0 or
less than the boundary for superiority α1. Any proper multiplicity adjustment
can be applied for p-values of intersection hypotheses involving more than
one elementary hypothesis. If all intersection hypotheses that includes H0j
demonstrates smaller p-values than α1 at this interim analysis, we early reject
the elementary null hypothesis H0j and stop the trial for superiority of the
treatment j. If any intersection that includes H0j has greater p-value than α0,
we early accept the elementary null hypothesis H0j and drop the treatment
j for futility. Otherwise, the trial continues to stage 2 with treatment j and
rejects H0j if combined stage-wise p-values for all relevant intersections are
smaller than the critical value c. At stage 2, intersections involving both
dropped and remaining treatments are replaced by intersections of remaining
treatments. For example, we assume that experimental treatment 1 is dropped
at interim analysis. Then, the 2nd stage p-value for the intersection hypothesis
involving H01 and H02 is replaced by the 2nd stage p-value for H02. H02 will
be rejected at stage 2 if C(p[1,H02], p[2,H02]) < c and C(p[1,H01
⋂
H02], p[2,H02]) < c,
where p[i,H02] is the p-value at stage i for H02 and p[i,H01
⋂
H02] is the p-value at
stage i for H01
⋂
H02.
15
Chapter 3
Bayesian Adaptive Design
Traditional frequentist designs such as group sequential designs and
combination test approaches have been developed to provide more flexibility in
clinical trials by introducing proper interim data analyses. In order to control
the overall type I error rate, however, these designs still depend in part on
pre-specified design components, e.g., the maximum number of stages, and
statistical inferences are only meaningful when these critical design features
are maintained as planned. In this regard, Bayesian methods can offer more
flexibility, as they can make various posterior inferences based on the data
without pre-determined design constraints or asymptotic assumptions of test
statistics [11, 12]. Bayesian methods directly derive a posterior distribution of
parameters given the data and thus do not require calculation of type I error in
advance for mid-trial adaptation. While conceptually a Bayesian design does
not require the evaluation of type I error, in practice, any real implementation
would include an extensive discussion of type I error under a variety of realistic
scenarios [11]. This chapter describes the concept of Bayesian methods and
an Bayesian adaptive design for the comparison study, which is summarized
as a step-by-step algorithm in the section 4.1.4. More extensive reviews about
Bayesian adaptive designs can be found in Berry et al. (2010) [11].
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3.1 A Bayesian Model for Adaptive Design
Bayesian models often incorporate additional information through prior
distributions of parameters and produce a posterior distribution so that infer-
ences are made based on the distribution of parameters given the data [29].
Priors can be constructed from various sources such as insights from experts
and results from previous analyses. Priors also can be non-informative if there
is no relevant prior knowledge. According to the Bayes theorem, the joint
posterior distribution is obtained from the following equation:
p(θ|y) = p(y|θ)p(θ)
p(y)
(3.1)
where y is observed data and θ is a parameter vector of interest. p(θ) is an
assumed prior distribution for the parameters.
3.1.1 A Bayesian Hierarchical Model for Multiplicity
One popular Bayesian approach in clinical trial designs is based on a
hierarchical Bayesian model, which borrows strength from the related sub-
populations. The related subpopulations can be different treatments on the
same disease or the same treatment on the related disease types. In a hi-
erarchical Bayesian approach, information from one treatment is shared with
other treatments through presumed underlying structure, and the result of one
treatment can provide information about the effect of the other related treat-
ments [11, 12]. For the Bayesian adaptive model in this report, a hierarchical
Bayesian model was constructed based on Thall et al. (2003) [12]. Thall et
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al. (2003) [12] proposed a clinical trial design for a disease with multiple sub-
types, allowing treatment effects to differ but correlated through a hierarchical
structure. By using a Bayesian hierarchical model, multiple treatments also
can be tested in multiple stages. For a rigorous discussion of a Bayesian view
of multiple testing problems, see, for example, Scott and Berger (2010) [33].
Suppose that we are interested in testing multiple one-sided null hy-
potheses in K stages, i.e., comparing multiple experimental treatments to one
standard treatment. We assume that there are J+1 treatments for the same
disease, where one is the standard treatment (treatment 0) and the others
are different experimental treatments (treatment 1,..,J). Similar to other de-
signs in this report, outcomes are considered as normal random variables with
treatment-specific means and the known common variance. Since they are
independent conditioned on the unknown treatment means, i-th observation
of j-th treatment, yij, has the following distribution:
yij|µj ∼ N(µj, σ2), i = 1, ..., njk, j = 0, ..., J (3.2)
where µj denotes the mean of j-th treatment, σ
2 denotes the known common
variance, and the njk denotes the number of patients enrolled in j-th treatment
up to stage k=1,..,K.
µj’s are different across treatments but allowed to be correlated by
presumed underlying structures. Therefore, this model assumes each µj follows
the same normal prior distribution with mean γ and variance τ 2:
µj ∼ N(γ, τ 2), j = 0, .., J (3.3)
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where γ is a normally distributed parameter with mean m and variance V ,
and τ 2 is a parameter whose inverse follows a Gamma distribution with the
parameters a and b.
µ ∼ N(m,V ) (3.4)
1/τ 2 ∼ Ga(a, b) (3.5)
These hyper parameters, m,V, a, b, are often determined in advance so
that µ and τ 2 have non-informative vague priors under the absence of any
relevant information. In this study, the values for m,V, a, b are determined as
follows to reflect this lack of prior information.
m = 0 (3.6)
V = 100 (3.7)
a = 0.01 (3.8)
b = 0.01 (3.9)
3.1.2 Posterior Estimation
Bayesian models make inferences based on posterior distributions, which
are usually estimated by Markov Chain Monte Carlo (MCMC). Markov Chain
Monte Carlo is a popular technique to simulate posterior distributions when
the model is too complicated to obtain direct estimation through traditional
methods. In this study, Gibbs sampling can be effectively exploited to gen-
erate posterior samples of parameters [30]. Gibbs Sampling is one of MCMC
19
methods and needs only full conditional posterior distributions of parameters.
Thus, it allows a convenient way to simulate the joint posterior distribution for
the models with well-known full conditional posterior distributions. At stage
k, the full conditional posterior distributions for the parameters in this study
are calculated as follows:
p(µj|γ, τ 2, y) = N
((
njk
σ2
+
1
τ 2
)−1(∑njk
i=1 yij
σ2
+
γ
τ 2
)
,
(
njk
σ2
+
1
τ 2
)−1)
(3.10)
p(γ|θ, τ 2, y) = N
((
J + 1
τ 2
+
1
V
)−1(∑J
j=0 µj
τ 2
+
m
V
)
,
(
J + 1
τ 2
+
1
V
)−1)
(3.11)
p(1/τ 2|θ, γ, y) = Ga
(
J + 1
2
+ a,
∑J
j=0(µj − γ)2
2
+ b
)
(3.12)
3.1.3 Decisions and Design
At each interim stage, experimental treatments are tested based on
their estimated posterior distributions to determine whether they should be
early stopped or proceed to the next stage. That is, i-th treatment is dropped
for futility if the posterior probability p(µi − µ0 > µj − µ0|y) is smaller than
α for the all other experimental treatment j:
p(µi − µj > 0|y) < α, for all j 6= i (3.13)
where α is a fixed cut-off value such as 0.025 or 0.05.
If this posterior probability is not smaller than α at least for one ex-
perimental treatment, the treatment continues to the next stage after interim
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adaptation such as sample size modification. When the trial reaches the final
stage K, the null hypotheses with respect to on-going treatments are exam-
ined individually at the final analysis using Bayes Factor. Bayes Factor is
a Bayesian approach for hypothesis testing, which summarizes evidence pro-
vided by data in favor of one hypothesis against the other hypothesis [31, 32].
Let the hypotheses for the i-th treatment effect be:
H0i : µi − µ0 ≤ 0, H1i : µi − µ0 > 0 (3.14)
Then, Bayes Factor is the ratio of probabilities that we observe data given H1i
versus H0i such that
BF10 =
p(y|H1i)
p(y|H0i) =
p(H1i|y)/p(H1i)
p(H0i|y)/p(H0i) (3.15)
where y is all previous data associated with the treatment i up to stage K. If
BF10 is greater than 3, we conclude that there is substantial evidence in favor
of H1 against H0 and reject the null hypothesis for the treatment i as the final
decision. If BF10 is not greater than 3, we cannot reject the null hypothesis
for the treatment i.
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Chapter 4
Comparison Study for Adaptive Designs
This chapter illustrates a simulation study that compares statistical
power of adaptive designs when multiple stages are conducted with multiple
treatments. The study mainly targets adaptive designs introduced in the pre-
vious chapters, but one fixed-sample design is also included to see the difference
with adaptive designs. The fixed-sample design in this study regards stages
as separate trials and only use the final stage data for the final decision. The
mid-stage data can be used to configure the next stage design. The detailed
simulation scenarios for four designs are given in the first section, and the
main findings from the study are discussed in the second section. The designs
are presented and compared in the following order: 1) fixed-sample design;
2) group sequential design; 3) combination test approach; and 4) Bayesian
adaptive design.
4.1 Simulation Scenarios
The simulation in this study includes seven scenarios for four designs,
two for each frequentist design and one for the Bayesian design. The trial
settings and assumptions are based on the simulation study of Bretz et al.
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(2009) [1] which compares adaptive designs based on combination tests in
various settings, but individual scenarios are extended to meet the unique
feature of designs considered in this study. This section first illustrates the
common trial settings for simulation, and then provides simulation algorithms
(or scenarios) for each design.
We assume that a trial is conducted in two stages with three treatments,
where two are the experimental treatment and the other is the standard (or
control) treatment. The experimental treatments are named treatment 1 and
2, while the standard treatment is treatment 0. One interim analysis and
one final analysis are allowed in this setting. As described in the previous
chapters, observations are normally distributed with treatment-specific means
µj, j = 0, 1, 2 and the common known variance σ
2. Here we follow the Britez
et al. (2009)’s assumption that σ2 = 62, µ0 = 0, µ1 = 2, and µ2 varying in
the interval (0,3].
The trial is aimed to compare each experimental treatment to the stan-
dard treatment, and all tests in this study are based on one-sided hypotheses
H0j : µj −µ0 ≤ 0, H1j : µj −µ0 > 0. The family-wise error rate α for frequen-
tist designs is controlled at significance level of 0.025. To address multiplicity
issue, Bonferroni correction and the closure principle are used for frequentist
designs as discussed before. The sample size per each treatment per stage is
set to 72 so that a single test has a statistical power of 0.8 when the true mean
difference is 2.
To compare performances of designs in terms of statistical power, suit-
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able power concept needs to be implemented throughout the simulation. The
general definition of statistical power is the probability of rejecting null hypoth-
esis when the alternative is true, but this is not obvious for multiple treatment
case with multiple null hypotheses. In this regard, this study computes power
as the probability of rejecting at least one false null hypothesis [34]. Since
this study only includes true alternative hypotheses (thus false null hypothe-
ses), the simulation measures statistical power by computing the proportion
of times at least one null hypothesis is rejected.
Overall, two adaptation rules are considered for the interim analysis
in this study. One is to continue with all treatments to the second stage
(adaptation I), and the other is to drop the inferior experiment treatment based
on the first stage mean value (adaptation II), i.e. drop treatment j if µˆj < µˆi
(frequentist) or p(µj > µi|y) < α (Bayesian). In the case that one treatment is
dropped at the interim analysis, the scheduled second stage sample size for the
discontinued treatment is evenly assigned to the continued treatments. These
interim adaptation rules can only be applied on frequentist designs when they
can maintain the family-wise error rate at pre-specified level, whereas there is
no restriction on the Bayesian design. For this reason, the above adaptation
rules were not included in the simulation for group sequential designs. The
fixed-sample design can exploit the rules because it derives the final decision
only based on the final stage, and the combination test approach allows the
interim adaptation by construction. Although the Bayesian design in this
study does not have restrictions on the interim rules, only adaptation II was
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included in the simulation due to the several practical reasons. For example,
posterior distributions of true means given the first stage data would not be
very different each other because of the relatively large variance of observations
and the vague priors. This leads to similar results for both interim rules, so
adaptation II was only implemented in this study (See appendix A).
Based on the trial settings above, seven simulation algorithms for the
four designs were produced. The scenarios share the common assumptions
and methodology to calculate statistical power, but follow the procedures cor-
responding to their own design features. For each scenario, 1000 trials were
simulated for each 1000 different µ2 ∈ (0, 3]. The whole process of analyses
was implemented using the statistical software R.
4.1.1 Algorithm for Fixed-Sample Design
In this study, a fixed-sample design is assumed to use only the second
stage data to derive the final decision for treatment differences. The first stage
data are used to determine which experimental treatment should be dropped
in case that adaptation II is considered. In case of adaptation I, practical
problems such as safety issues can be addressed based on the first stage data
although there is no change in the design. For adaptation I case, the algorithm
for the fixed-sample design is as follows:
1. Set µ0 = 0, µ1 = 2, µ2 = 0.003, σ
2 = 62, α = 0.025, n1 = n2 = 72
2. Set success=0
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3. Simulate observations for stage 1: Generate samples Y0j ∼ N(µ0, σ2), Y1j ∼
N(µ1, σ
2), Y2j ∼ N(µ2, σ2), j = 1, ..., n1, where Yij is j-th observation
from treatment i.
4. Simulate observations for stage 2: Generate samples Y0j ∼ N(µ0, σ2), Y1j ∼
N(µ1, σ
2), Y2j ∼ N(µ2, σ2), j = 1, ..., n2.
5. Test for the final decision: Based on the second-stage data, obtain the
second stage p-values p(2,1), p(2,2), and p(2,12) for three null hypotheses
H01 : µ1 − µ0 ≤ 0, H02 : µ2 − µ0 ≤ 0, and H01
⋂
H02, respectively. The
p-value for H01
⋂
H02 is calculated by min{1, 2min(p(2,1), p(2,2))} using
Bonferroni correction. If either [p(2,1) < α and p(2,12) < α] or [p(2,2) < α
and p(2,12) < α], increase success by one.
6. Calculate power: Repeat 2-5 steps 1000 times and calculate power as
success/1000
7. Increase µ2 by 0.003 and Repeat 2-6 steps by µ2 = 3
For adaptation II case, one experiment treatment is dropped based on
the first stage mean value, and the sample size for the discontinued treatment
is evenly reallocated to the continued treatments.
1. Set µ0 = 0, µ1 = 2, µ2 = 0.003, σ
2 = 62, α = 0.025, n1 = n2 = 72
2. Set success=0
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3. Simulate observations for stage 1: Generate samples Y0j ∼ N(µ0, σ2), Y1j ∼
N(µ1, σ
2), Y2j ∼ N(µ2, σ2), j = 1, ..., n1, where Yij is j-th observation
from treatment i.
4. Drop the inferior treatment: Obtain the mean value of each experimental
treatment and drop the treatment which has the smaller value.
5. Simulate observations for stage 2: Let Y ∗j be j-th observation from
the continued experimental treatment and µ∗ be the corresponding true
mean. Generate samples Y0j ∼ N(µ0, σ2), Y ∗j ∼ N(µ∗, σ2), j = 1, ..., n∗,
where n∗ = n2 + n1/2.
6. Test for the final decision: Based on the second-stage data, obtain the
second stage p-value p(2,∗) for the null hypothesis H0∗ : µ ∗ −µ0 ≤ 0. If
p(2,∗) < α, increase success by one.
7. Calculate power: Repeat 2-6 steps 1000 times and calculate power as
success/1000
8. Increase µ2 by 0.003 and Repeat 2-7 steps by µ2 = 3
4.1.2 Algorithm for Group Sequential Design
The group sequential designs included in this study are two classic
designs: 1) Pocock’s design and 2) O’Brien and Fleming’s Design. These
group sequential designs do not allow interim adaptation other than early
stopping for superiority. Thus, adaptation rule I and II for this study were
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not considered here, and instead the algorithms follow their own rules, i.e.,
stopping an experimenal treatment at interim if test statistics are greater
than pre-specified critical values. The critical values for two designs were
obtained from the simulation based on three equal-mean treatments with the
significance level 0.025. The calculated Pocock’s critical value is 2.178, and
O’Brien and Fleming’s is 1.977. The following is an algorithm for the group
sequential design when Pocock’s design is used.
1. Set µ0 = 0, µ1 = 2, µ2 = 0.003, σ
2 = 62, n1 = n2 = 72, cPO = 2.178
2. Set success=0
3. Simulate observations for stage 1: Generate samples Y0j ∼ N(µ0, σ2), Y1j ∼
N(µ1, σ
2), Y2j ∼ N(µ2, σ2), j = 1, ..., n1, where Yij is j-th observation
from treatment i.
4. Test for early stopping at interim analysis: Based on the first stage
data, obtain z-statistics Z1 =
Y¯1−Y¯0√
2σ2/n1
and Z2 =
Y¯2−Y¯0√
2σ2/n1
for the null
hypotheses H01 : µ1 − µ0 ≤ 0 and H02 : µ2 − µ0 ≤ 0, respectively.
The hypothesis test for H01
⋂
H02 can be conducted by max(Z1, Z2) ≥
cPO∗ using Bonferroni correction, where cPO∗ is a constant such that
p(Z > cPO∗) = p(Z > cPO)/2, Z ∼ N(0, 1). If either [Z1 ≥ cPO and
max(Z1, Z2) ≥ cPO∗] or [Z2 ≥ cPO and max(Z1, Z2) ≥ cPO∗], increase
success by one and jump to step 7 (stop a trial). Otherwise, continue to
step 5.
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5. Simulate observations for stage 2: Generate samples Y0j ∼ N(µ0, σ2), Y1j ∼
N(µ1, σ
2), Y2j ∼ N(µ2, σ2), j = 1, ..., n2.
6. Test for the final decision: Based on the first and second stage data,
obtain z-statistics Z1 and Z2 for the null hypotheses H01 : µ1−µ0 ≤ 0 and
H02 : µ2 − µ0 ≤ 0, respectively. If either [Z1 ≥ cPO and max(Z1, Z2) ≥
cPO∗] or [Z2 ≥ cPO and max(Z1, Z2) ≥ cPO∗], increase success by one.
7. Calculate power: Repeat 2-6 steps 1000 times and calculate power as
success/1000
8. Increase µ2 by 0.003 and Repeat 2-7 steps by µ2 = 3
The O’Brien and Fleming’s design has the exactly same procedure ex-
cept different critical values for hypothesis testings. Let cOB = 1.977. Instead
of the critical value of Pocock’s, cOB
√
2 is used at the interim analysis, and
cOB is used at the final analysis. Critical values to test H01
⋂
H02 also should
be computed differently for interim and final analyses based on cOB
√
2 and
cOB.
4.1.3 Algorithm for Combination Test Approach
Adaptive designs based on combination tests allow early stopping at
interim based on the pre-determined α0 and α1 values. However, the choice of
these values is usually application-specific and depends on a case-by-case basis.
For this reason, a non-binding rule was considered here by setting α0 = 1 and
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α1 = 0. Non-binding rules can still provide flexible interim adaptation, but
have more conservative power. The critical values for two adaptation rules
were obtained from the simulation using three equal-mean treatments, which
results in 0.0406 and 0.0300 for adaptation I and adaptation II, respectively.
The stage wise p-values were combined using the weighted inverse normal
combination function with weights w1 =
√
n1/(n1 + n2), w2 =
√
n2/(n1 + n2).
For adaptation I case, the algorithm for the combination approach is:
1. Set µ0 = 0, µ1 = 2, µ2 = 0.003, σ
2 = 62, c = 0.0406, n1 = n2 = 72
2. Set success=0
3. Simulate observations for stage 1: Generate samples Y0j ∼ N(µ0, σ2), Y1j ∼
N(µ1, σ
2), Y2j ∼ N(µ2, σ2), j = 1, ..., n1, where Yij is j-th observation
from treatment i.
4. Calculate the first stage p-values: Based on the first stage data, obtain
the first stage p-values p(1,1), p(1,2), and p(1,12) for three null hypotheses
H01 : µ1 − µ0 ≤ 0, H02 : µ2 − µ0 ≤ 0, and H01
⋂
H02, respectively. The
p-value for H01
⋂
H02 is calculated by min{1, 2min(p(1,1), p(1,2))} using
Bonferroni correction.
5. Simulate observations for stage 2: Generate samples Y0j ∼ N(µ0, σ2), Y1j ∼
N(µ1, σ
2), Y2j ∼ N(µ2, σ2), j = 1, ..., n2.
6. Calculate the second stage p-values: Based on the second-stage data,
obtain the second stage p-values p(2,1), p(2,2), and p(2,12) for three null
30
hypotheses H01 : µ1− µ0 ≤ 0, H02 : µ2− µ0 ≤ 0, and H01
⋂
H02, respec-
tively. The p-value forH01
⋂
H02 is calculated bymin{1, 2min(p(2,1), p(2,2))}
using Bonferroni correction.
7. Test for the final decision: Let C(p,q) denotes the weighted inverse
normal combination function with weights w1 =
√
n1/(n1 + n2), w2 =√
n2/(n1 + n2). If either [C(p(1,1), p(2,1)) < c and C(p(1,12), p(2,12)) < c] or
[C(p(1,2), p(2,2)) < c and C(p(1,12), p(2,12)) < c], increase success by one.
8. Calculate power: Repeat 2-7 steps 1000 times and calculate power as
success/1000
9. Increase µ2 by 0.003 and Repeat 2-8 steps by µ2 = 3
For adaptation II case, one experiment treatment is dropped at the
interim based on the first stage mean value, and the sample size for the dis-
continued treatment is evenly reallocated to the continued treatments.
1. Set µ0 = 0, µ1 = 2, µ2 = 0.003, σ
2 = 62, c = 0.0300, n1 = n2 = 72
2. Set success=0
3. Simulate observations for stage 1: Generate samples Y0j ∼ N(µ0, σ2), Y1j ∼
N(µ1, σ
2), Y2j ∼ N(µ2, σ2), j = 1, ..., n1, where Yij is j-th observation
from treatment i.
4. Calculate the first stage p-values: Based on the first stage data, obtain
the first stage p-values p(1,1), p(1,2), and p(1,12) for three null hypotheses
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H01 : µ1 − µ0 ≤ 0, H02 : µ2 − µ0 ≤ 0, and H01
⋂
H02, respectively. The
p-value for H01
⋂
H02 is calculated by min{1, 2min(p(1,1), p(1,2))} using
Bonferroni correction.
5. Drop the inferior treatment: Obtain the mean value of each experimental
treatment and drop the treatment which has the smaller value.
6. Simulate observations for stage 2: Let Y ∗j be the j-th observation from
the continued experimental treatment and µ∗ be the corresponding true
mean. Generate samples Y0j ∼ N(µ0, σ2), Y ∗j ∼ N(µ∗, σ2), j = 1, ..., n∗,
where n∗ = n2 + n1/2.
7. Calculate the second stage p-value: Based on the second stage data,
obtain the second stage p-value p(2,∗) for H0∗ : µ ∗ −µ0 ≤ 0.
8. Test for the final decision: Let C(p,q) denotes the weighted inverse
normal combination function with weights w1 =
√
n1/(n1 + n∗), w2 =√
n ∗ /(n1 + n∗). If C(p(1,∗), p(2,∗)) < c and C(p(1,12), p(2,12)) < c, increase
success by one.
9. Calculate power: Repeat 2-8 steps 1000 times and calculate power as
success/1000
10. Increase µ2 by 0.003 and Repeat 2-9 steps by µ2 = 3
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4.1.4 Algorithm for Bayesian Adaptive Design
The Bayesian adaptive design proposed in the previous section provides
multiple treatment testing based on the posterior distributions of parameters.
Gibbs sampling method was exploited to generate posterior samples from the
proposed Bayesian model, with one chain run with 500 iterations. The number
of MCMC iterations is relatively small since each chain converges very quickly
from the simulated data (See appendix B). As discussed earlier, it was expected
that two adaptation cases show little difference in terms of statistical power.
Thus, only adaptation II was implemented in this simulation, dropping one
inferior experimental treatment based on the distributional difference p(µ2 −
µ1 > 0|y) < α or p(µ1 − µ2 > 0|y) < α.
1. Set µ0 = 0, µ1 = 2, µ2 = 0.003, σ
2 = 62, α = 0.025, n1 = n2 = 72
2. Set success=0
3. Simulate observations for stage 1: Generate samples Y0j ∼ N(µ0, σ2), Y1j ∼
N(µ1, σ
2), Y2j ∼ N(µ2, σ2), j = 1, ..., n1, where Yij is j-th observation
from treatment i.
4. Drop if there is an inferior treatment: Estimate posterior distributions
given the first stage data by Gibbs sampling. Drop treatment 1 if p(µ1−
µ2 > 0|y) < α, or drop treatment 2 if p(µ2 − µ1 > 0|y) < α. Otherwise,
proceed with all treatments.
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5. Simulate observations for stage 2: If one of treatment is dropped, gener-
ate samples Y0j ∼ N(µ0, σ2), Y ∗j ∼ N(µ∗, σ2), j = 1, ..., n∗, where Y ∗j
is the j-th observation from the continued experimental treatment, µ∗ is
the corresponding true mean, and n∗ = n2 + n1/2. Otherwise, generate
samples Y0j ∼ N(µ0, σ2), Y1j ∼ N(µ1, σ2), Y2j ∼ N(µ2, σ2), j = 1, ..., n2.
6. Derive the final decision: Based on the first and second stage data,
estimate posterior distributions by Gibbs sampling. If one of treatment
was dropped, test H0∗ : µ ∗ −µ0 ≤ 0 vs. H1∗ : µ ∗ −µ0 > 0 using Bayes
factor. Increase success by one when the Bayes factor is greater than 3
in favor of the alternative hypothesis. If all treatments were continued
to stage 2, test H0i : µi − µ0 ≤ 0 vs. H1i : µi − µ0 > 0 for treatment
i=1,2 individually using Bayes factor. Increase success by one if one of
Bayes factors is greater than 3 in favor of the corresponding alternative
hypothesis.
7. Calculate power: Repeat 2-6 steps 1000 times and calculate power as
success/1000
8. Increase µ2 by 0.003 and Repeat 2-7 steps by µ2 = 3
4.2 Results
This section presents results of the simulation study described in the
previous section. Since statistical power increased in order of fixed-sample de-
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signs, group sequential designs, combination test approaches, and the Bayesian
adaptive design, pairwise comparisons were made between fixed-sample versus
group sequential designs, group sequential versus combination test approaches,
and combination test approaches versus the Bayesian adaptive design.
4.2.1 Fixed-Sample vs. Group Sequential Designs
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Figure 4.1: Statistical power of Fixed-sample vs. Group sequential designs
The Figure 4.1 shows the power of fixed-sample and group sequen-
tial designs. As discussed earlier, two group sequential designs, Pocock’s and
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O’Brien and Fleming’s, cannot incorporate interim adaptation other than early
stopping for superiority. For fixed-sample design, two adaptation cases were
considered, where one is the case in which all treatments proceed to the second
stage (adaptation I), and the other is dropping the inferior experimental treat-
ment based on the mean value of the first stage (adaptation II). The power
trend with respect to the selected values of µ2 is also given as numbers at the
end of this section (Table 4.1).
Overall, the graph demonstrates that group sequential designs have
greater power than the fixed-sample design regardless of types of adaptation.
Different amount of information may play an important role in this gap, since
larger information leads to more power in hypothesis testing. Fixed-sample
design derives the final decision only based on the second stage data, whereas
group sequential designs exploit all stage data unless they stop a trial early at
the interim. The difference between fixed-sample and group sequential designs
decreases as the value of second treatment mean, µ2, increases.
For the fixed-sample design, the power of adaptation II is greater than
that of adaptation I due to the increased sample-sizes from the dropped treat-
ment. Note that the power of adaptation II is not monotonous in µ2. This can
be explained by the behavior of treatment selection as follows [1, 35]. When
µ2 is much smaller than µ1 = 2, there is little chance for the treatment 2 to be
selected for the stage 2. As µ2 increases toward µ1, however, the probability
of selecting treatment 2 also increases although µ2 is still less than µ1. A trial
may loses statistical power until it reaches the point where both treatments
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equally effective, because the inferior treatment can be tested for the final
decision.
For the group sequential designs, O’Brien and Fleming’s design shows
greater power than Pocock’s design. This is not surprising because these two
designs are exactly the same except the critical values used in hypothesis
testings. O’Brien and Fleming’s design has the smaller second stage critical
value (and thus larger critical region) compared to Pocock’s: 1.977 (O’Brien
and Fleming’s) and 2.178 (Pocock’s) in this study. As a result, it is more likely
that the power of O’Brien and Fleming’s is higher than that of Pocock’s.
4.2.2 Group Sequential vs. Combination Test Approaches
In Figure 4.2, group sequential and combination test approaches were
compared in terms of statistical power. The two group sequential designs,
Pocock’s and O’Brien and Fleming’s, allow only early stopping for superiority
at the interim analysis, while the combination test approach allows two adap-
tation cases: continue to the second stage with all treatments (adaptation I)
or only with the superior treatment based on the first stage mean value (adap-
tation II). In this comparison, both group sequential and combination test
approaches incorporate all stage data for the final decision, but use different
test statistics: z-statistics (group sequential design) and p-values (combina-
tion test approach). Designs based on p-values can be conservative than those
based on z-statistics, because p-values are not sufficient statistics and thus
can lose information contained in data [15]. Note that z-statistics are from
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Figure 4.2: Statistical power of Group sequential vs. Combination test ap-
proaches
mean value of the data and preserve all the information in data as a sufficient
statistic.
From the Figure 4.2, it can be seen that the combination test approach
performs better than group sequential designs. This is consistent with the re-
sults from previous researches (i.e. [35]). The combination test approach with
adaptation II has the largest power among four cases in this comparison, indi-
cating that reallocated sample sizes compensated possible loss of information
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caused by p-values. This shows that the conservative nature of test statistics
in the combination test approach can be overcome by the advantage of flexible
interim adaptation. The Pocock’s design has the lowest power among the four
cases, and the other cases are located between Pocock’s and the combination
test approach with adaptation II. The power trend with respect to the selected
values of µ2 is also given as numbers at the end of this section (Table 4.1).
For the combination test approach with adaptation I and the O’Brien
and Fleming’s design, it is hard to say that one is better than the other.
O’Brien and Fleming’s design shows slightly higher power than the other for
small values of µ2, but shows lower power for moderate and large values of
µ2. This can be partly explained by the difference in test statistics, since
combination test approaches based on p-values and the closure principle do
not lead to sufficient test statistics when multiple treatments are considered
[35]. The simulation result in this study indicates that the use of insufficient
statistics can lower the power, while the effect is alleviated by the large value
of the true mean (µ2 in this study).
4.2.3 Combination Test Approach vs. Bayesian Adaptive Design
For the final comparison, the power of the Bayesian adaptive design
was plotted with the power of combination test approach (Figure 4.3). The
combination test approach assumes two adaptation rules, I and II, and the
Bayesian adaptive design only considers adaptation rule II because of the in-
difference of the results. Although the adaptation rule II is implemented for
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Figure 4.3: Statistical power of Combination test approaches vs. Bayesian
adaptive design
both combinatio n test and Bayesian adaptive designs, dropping criterion at
the interim is different each other. The combination test approach drops the
inferior treatment based on the mean value of the first stage data, while the
Bayesian model make this decision by comparing posterior distributions of
parameters conditioned on the first stage data. For the final decision, both
combination test approaches and the Bayesian adaptive design exploit all stage
data but use different statistics: p-values for the combination test approach
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and posterior distributions for the Bayesian model. In addition, unlike the
Bayesian model, the combination test approach uses Bonferroni correction
and the closure principle to deal with the multiplicity issue.
In Figure 4.3, the Bayesian model shows larger power than the com-
bination test approaches regardless of types of adaptation. The difference is
substantial for small values of µ2 and decreases as µ2 increases. Note that the
Bayesian model is hardly dropping a treatment at the interim analysis, and
thus, there are much fewer chances to increase second stage sample size than
the combination test approach with the same adaptation. This indicates that
Bayesian model has strong points in terms of power other than interim adap-
tation or sample size reallocation. There can be several possible explanations.
First, the Bayesian model derives the final decision based on the posterior dis-
tributions of parameters. These distributions are conditioned on the full data,
so there is usually no loss of information compared to insufficient statistics
such as p-values. Second, the Bayesian model does not need to incorporate
methods for type I error rate such as Bonferroni correction and the closure
principle. Especially for the Bonferroni correction, it is known that the type
I error rate is controlled in a very conservative sense. This means that the
actual type I error rate is mostly smaller than the significance level, resulting
in less power than expected. Overall, the Bayesian model performs better than
all the other designs included in this study. The power trend with respect to
the selected values of µ2 is also given as numbers at the end of this section
(Table 4.1).
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Chapter 5
Discussion
The present report provided a comparative investigation of both fre-
quentist and Bayesian adaptive designs when more than one experimental
treatments are tested in multiple stages. Researches on the adaptive designs
have been mostly restricted to limited comparison of frequentist methods, and
there is little evidence for the relative performance of Bayesian models or for
the situation when multiple treatments are involved in a trial. To address
this issue, various adaptive designs were included in this study. They are
mainly three designs: group sequential design, combination test approach,
and Bayesian adaptive design. More precisely, Pocock’s [3] and O’Brien and
Fleming’s designs [4] for the group sequential design, Bretz et al. (2009) model
[1] for the combination test approach, and a hierarchical Bayesian model based
on Thall et al. (2003) [12] for the Bayesian adaptive design were considered.
The comparison was made through a simulation study under various scenarios,
focusing on statistical power of the different designs. The simulation was based
on a two-stage clinical trial with one interim analysis and assumed two different
interim adaptation rules for the all designs except group sequential designs. A
fixed-sample design was also included in simulation as a non-adaptive baseline
design.
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According to the simulation results, it was shown that the Bayesian
adaptive design outperforms than all other designs in the setting of this study.
The power of the combination test approach was consistently higher than
O’Brien and Fleming’s design when there is an early-dropped treatment which
allows sample size reallocation, but not always higher when there is no dropped
treatment. O’Brien and Fleming’s design was better than Pocock’s design
as expected. It was also emphasized that all adaptive designs demonstrated
higher statistical power compared to the non-adaptive fixed-sample design re-
gardless of adaptation rules considered in this study. Overall, statistical power
increased in order of fixed-sample design, group sequential design, combination
test approach, and Bayesian adaptive design. The difference decreased as the
true mean of the second experimental treatment increased.
The findings of the current study are consistent with Bretz et al. (2009)
[1] in that combination test approaches show higher power than fixed-sample
designs regardless of the interim adaptation rules. The results of these two
designs from both studies seem exactly the same since the assumptions used
in this study are mostly based on those of Bretz et al. (2009). The findings of
the present study also confirm the findings of Tsiatis and Mehta (2003) [13]
and Jennison and Turnbull(2003,2006) [14, 15] that there can be reduction of
power due to the use of insufficient statistics. In the case of multiple experi-
mental treatments, however, the reduction was small and appeared only when
not all experimental treatments are sufficiently different from the standard.
This result is consistent with the insight of Kelly et al (2005) [16] but was not
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shown in the study of Friede and Stallard (2008) [35]. The current study also
investigated the impact of interim adaptation regarding sample size realloca-
tion, which was not considered in Friede and Stallard (2008). The superior
power of the combination test approach indicates that the use of insufficient
statistics can be compensated by appropriate interim adaptation. For the
Bayesian adaptive design, the present study provided new evidence of rela-
tive performance in terms of statistical power. The Bayesian adaptive model
demonstrated higher power with great flexibility, compared to the various fre-
quentist adaptive designs included in this study. This result has important
implication for the future design development and may help us to find better
adaptive designs in clinical trials.
The findings in this report are subject to at least the following limita-
tions. First, the study focused on only a few adaptive designs in clinical trials.
There are other group sequential designs which incorporate various interim
situations and other combination test approaches with different combination
functions [36, 37]. The Bayesian adaptive model can also be extended to take
into account various design considerations. Since it is expected that different
design assumptions affect statistical power differently, the results in this study
cannot be extrapolated to all adaptive designs. Second, the simulation study
is based on the specific assumptions and scenarios. The design considerations
are mainly influenced by the primary study objectives in practice, and the
setting of this study is not always satisfied. For example, the power concept
measuring the probability of rejecting at least one false null hypothesis may
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not be appropriate in some settings. Power can be defined as the probability
of rejecting all false null hypotheses or adjusted in many different ways to ful-
fill the specific goals of trials [34]. Finally, the Bayesian model in this study
assumed only non-informative priors. Informative priors improve the quality
of analyses by delivering additional information. In most cases, clinical trials
are likely to have previous researches, trials or standard regimens. Thus, if
there exist qualified prior information, the Bayesian model can result in more
practical and insightful conclusions.
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Appendix A
Two Adaptation Cases in the Bayesian Model
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Figure A.1: Statistical power of the Bayesian model: two adaptation cases
A short simulation result of the Bayesian model comparing two adap-
tation cases (Figure A.1). Each case was implemented using 200 trials with
200 different µ2 as an example. The figure demonstrates that two adaptation
cases are not very different in terms of power in the setting of this study.
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Appendix B
Convergence in the Bayesian Model
Posterior distributions of the Bayesian model were estimated using
Gibbs sampling with 500 iterations, and samples mostly showed sufficient con-
vergence to the target distributions. As an example, the following illustrates
convergence of a posterior sample conditioned on first stage data in a trial. µ2
was chosen to be 3.
First, Geweke diagnostic [38] was calculated as one of the convergence
diagnostics. Geweke diagnostic is based on a test for equality of means of the
first 10% and the last 50% of a Markov chain. This asymptotically has normal
distribution under the equality and uses a standard Z-score as a test statistic.
From a posterior sample drawn by Gibbs sampling, Geweke diagnostic showed
0.4529 for µ0, -0.2952 for µ1, 0.4215 for µ2, -1.136 for γ, and -0.8639 for τ
2.
Since no values are bigger than 1.96, it can be concluded that this chain is
converged to the target distribution. (1.96 is corresponding to 0.05 significance
level for a two-sided test)
Next, convergence was visually inspected through trace plots of param-
eters (Figure B.1). According to the plots, there is no evidence of severe lack
of convergence in this sample.
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Figure B.1: Trace plots of parameters for the Bayesian model
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